These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 18025850)

  • 1. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gene mutation in recurrent superficial bladder cancer.
    Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
    J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.
    Shiraishi K; Eguchi S; Mohri J; Kamiryo Y
    Anticancer Res; 2003; 23(4):3475-8. PubMed ID: 12926093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
    Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
    J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
    Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
    Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ; Baunoch DA; Stadler WM
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
    Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
    Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.